-
2024-519494-19-00
5
2025-12-22
Nutritional and metabolic diseases
-
2024-518167-35-01
4
2025-12-19
Patients with Metastatic Osteosarcoma
-
2024-512298-28-00
11
2025-12-18
Neovascular age-related macular degeneration
-
2024-514500-14-00
5
2025-12-15
Participants with KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous
-
2024-515125-28-00
4
2025-12-08
Non-obstructive hypertrophic cardiomyopathy
-
2025-523083-21-00
5
2025-12-08
PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor
-
2024-517136-21-00
5
2025-12-05
Renal Cell Carcinoma
-
2025-522452-16-00
4
2025-12-05
Endometriosis related pain
-
2025-521398-15-00
5
2025-12-04
Immune system diseases
-
2025-521381-10-00
5
2025-12-03
Moderately to Severely Active Ulcerative Colitis
-
2025-521281-97-00
5
2025-12-02
Non-Small Cell Lung Cancer (NSCLC)
-
2025-522291-83-00
5
2025-11-27
Atopic Keratoconjunctivitis
-
2024-519976-19-00
5
2025-11-26
Asthma with type 2 inflammation characterized by an eosinophilic pheno
-
2025-520658-12-00
4
2025-11-20
Idiopathic Pulmonary Fibrosis (IPF)
-
2024-513332-17-00
7
2025-11-19
KCNT1-related Developmental and Epileptic Encephalopathy
-
2024-512849-17-00
5
2025-11-14
Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Di
-
2024-519654-37-00
10
2025-11-07
Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
-
2024-518969-98-00
5
2025-11-04
Neurotrophic Keratopathy
-
2024-519917-72-00
5
2025-10-29
Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with C
-
2024-517121-10-00
5
2025-10-17
Menstrual Migraine
-
2025-520564-17-00
5
2025-10-16
Hidradenitis suppurativa (HS)
-
2025-521188-11-00
5
2025-10-15
Type 2 diabetes
-
2025-520490-38-00
3
2025-10-13
Haemophilia A with or without inhibitors. Proposed indication under de
-
2024-520137-74-00
4
2025-10-10
Idiopathic Short Stature (ISS)